HomeCompareGFTRF vs MRK

GFTRF vs MRK: Dividend Comparison 2026

GFTRF yields 20000.00% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GFTRF wins by $52481917574412746752.00M in total portfolio value
10 years
GFTRF
GFTRF
● Live price
20000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52481917574412746752.00M
Annual income
$51,970,745,957,167,775,000,000,000.00
Full GFTRF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — GFTRF vs MRK

📍 GFTRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGFTRFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GFTRF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GFTRF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GFTRF
Annual income on $10K today (after 15% tax)
$1,700,000.00/yr
After 10yr DRIP, annual income (after tax)
$44,175,134,063,592,610,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, GFTRF beats the other by $44,175,134,063,592,610,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GFTRF + MRK for your $10,000?

GFTRF: 50%MRK: 50%
100% MRK50/50100% GFTRF
Portfolio after 10yr
$26240958787206373376.00M
Annual income
$25,985,372,978,583,888,000,000,000.00/yr
Blended yield
99.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

GFTRF
No analyst data
Altman Z
-832.5
Piotroski
2/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GFTRF buys
0
MRK buys
0
No recent congressional trades found for GFTRF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGFTRFMRK
Forward yield20000.00%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$52481917574412746752.00M$56.8K
Annual income after 10y$51,970,745,957,167,775,000,000,000.00$9,798.13
Total dividends collected$52448189483771600896.00M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GFTRF vs MRK ($10,000, DRIP)

YearGFTRF PortfolioGFTRF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$2,010,700$2,000,000.00$11,206$366.19+$2.00MGFTRF
2$377,983,225$375,831,775.70$12,650$502.35+$377.97MGFTRF
3$66,433,479,469$66,029,037,418.28$14,407$694.19+$66433.47MGFTRF
4$10,916,985,471,987$10,845,901,648,955.73$16,585$967.82+$10916985.46MGFTRF
5$1,677,384,363,769,318$1,665,703,189,314,291.80$19,342$1,363.89+$1677384363.75MGFTRF
6$240,985,175,079,139,100$239,190,373,809,905,920.00$22,913$1,947.19+$240985175079.12MGFTRF
7$32,373,573,631,143,694,000$32,115,719,493,809,017,000.00$27,662$2,823.89+$32373573631143.66MGFTRF
8$4,066,766,648,320,630,000,000$4,032,126,924,535,306,000,000.00$34,159$4,173.35+$4066766648320630.00MGFTRF
9$477,730,483,406,513,300,000,000$473,379,043,092,810,300,000,000.00$43,337$6,308.80+$477730483406513344.00MGFTRF
10$52,481,917,574,412,750,000,000,000$51,970,745,957,167,775,000,000,000.00$56,776$9,798.13+$52481917574412746752.00MGFTRF

GFTRF vs MRK: Complete Analysis 2026

GFTRFStock

Gold'n Futures Mineral Corp., an exploration stage company, engages in acquisition and exploration of precious and base metals properties in Canada. The company's projects include the Hercules gold project consists of 372 contiguous claim cells covering an area of 6,951 hectares located to the northeast of Thunder Bay, Ontario; and the Brady gold project located in south central Newfoundland. Its projects include the Cree Lake gold project comprises 151 single cell and 43 boundary claims covering approximately 4,074 hectares located in Swayze; and Handcamp project consists of two mineral claims covering 7,500 hectares located in central Newfoundland. The company was formerly known as European Metals Corp. and changed its name to Gold'n Futures Mineral Corp. in July 2020. Gold'n Futures Mineral Corp. is headquartered in Toronto, Canada.

Full GFTRF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this GFTRF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GFTRF vs SCHDGFTRF vs JEPIGFTRF vs OGFTRF vs KOGFTRF vs MAINGFTRF vs JNJGFTRF vs ABBVGFTRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.